{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:41:13Z","timestamp":1780090873421,"version":"3.54.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.xcrm.2025.101967","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T10:37:01Z","timestamp":1739183821000},"page":"101967","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Nanrilkefusp alfa (SOT101), an IL-15 receptor \u03b2\u03b3 superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0741-2118","authenticated-orcid":false,"given":"Stephane","family":"Champiat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Garralda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Galvao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe A.","family":"Cassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Gomez-Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iphigenie","family":"Korakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Grell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aung","family":"Naing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"LoRusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romana","family":"Mikyskova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Podzimkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Reinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaissa","family":"Ouali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreu","family":"Schoenenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Kiemle-Kallee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Tillmanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Sachse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Moebius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radek","family":"Spisek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bechard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka Palova","family":"Jelinkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Adkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelien","family":"Marabelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.101967_bib1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1600-065X.2008.00604.x","article-title":"Twelve immunotherapy drugs that could cure cancers","volume":"222","author":"Cheever","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.xcrm.2025.101967_bib2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-014-0026-0","article-title":"High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014","volume":"2","author":"Dutcher","year":"2014","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.101967_bib3","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.xcrm.2025.101967_bib4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T\u00a0cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.101967_bib5","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-17-2451","article-title":"A first-in-human phase I study of subcutaneous outpatient recombinant human IL15 (rhIL15) in adults with advanced solid tumors","volume":"24","author":"Miller","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.101967_bib6","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1158\/1078-0432.CCR-18-0945","article-title":"Phase I trial of ALT-803, a novel recombinant IL15 complex, in patients with advanced solid tumors","volume":"24","author":"Margolin","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.101967_bib7","article-title":"Interleukin-15 and cancer: some solved and many unsolved questions","volume":"8","author":"Fiore","year":"2020","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.101967_bib8","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3389\/fimmu.2020.00868","article-title":"IL-15 in the combination immunotherapy of cancer","volume":"11","author":"Waldmann","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.101967_bib9","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1074-7613(00)80564-6","article-title":"Potent and selective stimulation of memory-phenotype CD8+ T\u00a0cells in\u00a0vivo by IL-15","volume":"8","author":"Zhang","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2025.101967_bib10","doi-asserted-by":"crossref","first-page":"11445","DOI":"10.1073\/pnas.200363097","article-title":"IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice","volume":"97","author":"Marks-Konczalik","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2025.101967_bib11","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1158\/2326-6066.CIR-15-0009","article-title":"The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy","volume":"3","author":"Waldmann","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2025.101967_bib12","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1074\/jbc.M508624200","article-title":"Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta\/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins","volume":"281","author":"Mortier","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.xcrm.2025.101967_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jmb.2008.07.019","article-title":"The exon-3-encoded domain of IL-15ralpha contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Ralpha","volume":"382","author":"Bouchaud","year":"2008","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.xcrm.2025.101967_bib14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1084\/jem.20082013","article-title":"IL-15 trans-presentation promotes human NK cell development and differentiation in\u00a0vivo","volume":"206","author":"Huntington","year":"2009","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.xcrm.2025.101967_bib15","doi-asserted-by":"crossref","first-page":"6217","DOI":"10.1073\/pnas.1019167108","article-title":"IL-15 transpresentation promotes both human T-cell reconstitution and T-cell-dependent antibody responses in\u00a0vivo","volume":"108","author":"Huntington","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2025.101967_bib16","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4049\/jimmunol.1600019","article-title":"IL-15 trans-signaling with the superagonist RLI promotes effector\/memory CD8+ T\u00a0cell responses and enhances antitumor activity of PD-1 antagonists","volume":"197","author":"Desbois","year":"2016","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.xcrm.2025.101967_bib17","article-title":"IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment","volume":"8","author":"Desbois","year":"2020","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.101967_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.989895","article-title":"SOT101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity","volume":"13","author":"Antosova","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.101967_bib19","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1158\/1535-7163.MCT-09-0275","article-title":"High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer","volume":"8","author":"Bessard","year":"2009","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.xcrm.2025.101967_bib20","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.3747\/co.25.3840","article-title":"Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges","volume":"25","author":"Nixon","year":"2018","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.xcrm.2025.101967_bib21","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","article-title":"The next decade of immune checkpoint therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.101967_bib22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.101967_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.101967_bib24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.cytogfr.2017.06.011","article-title":"Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors","volume":"36","author":"Dammeijer","year":"2017","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.xcrm.2025.101967_bib25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40364-020-00212-5","article-title":"Resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives","volume":"8","author":"Sun","year":"2020","journal-title":"Biomark. Res."},{"key":"10.1016\/j.xcrm.2025.101967_bib26","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","article-title":"Tumor immune contexture is a determinant of anti-CD19 CAR T\u00a0cell efficacy in large B cell lymphoma","volume":"28","author":"Scholler","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.101967_bib27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cytogfr.2017.08.002","article-title":"Immunobiology of the IL-15\/IL-15Ralpha complex as an antitumor and antiviral agent","volume":"38","author":"Guo","year":"2017","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.xcrm.2025.101967_bib28","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.immuni.2020.10.020","article-title":"Antagonistic inflammatory phenotypes dictate tumor fate and response to immune checkpoint blockade","volume":"53","author":"Bonavita","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2025.101967_bib29","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96219","article-title":"Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect","volume":"3","author":"Felices","year":"2018","journal-title":"JCI insight"},{"key":"10.1016\/j.xcrm.2025.101967_bib30","doi-asserted-by":"crossref","first-page":"21647","DOI":"10.1073\/pnas.1012128107","article-title":"Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15\/IL-15Ralpha complexes","volume":"107","author":"Elpek","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2025.101967_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aag0479","article-title":"The discontinuity theory of immunity","volume":"1","author":"Pradeu","year":"2016","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.xcrm.2025.101967_bib32","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1182\/blood-2010-03-275438","article-title":"Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates","volume":"116","author":"Lugli","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.101967_bib33","article-title":"Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors","volume":"9","author":"Conlon","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.101967_bib34","unstructured":"National Comprehensive Cancer Network. NCCN Guideline: Squamous cell skin cancer, version 1.2024. https:\/\/www.nccn.org\/."},{"key":"10.1016\/j.xcrm.2025.101967_bib35","article-title":"Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis","volume":"9","author":"Rischin","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.101967_bib36","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.annonc.2021.07.008","article-title":"Pembrolizumab for locally advanced and recurrent\/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial","volume":"32","author":"Hughes","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2025.101967_bib37","article-title":"Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma","volume":"11","author":"Clingan","year":"2023","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.101967_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15123180","article-title":"Cetuximab for immunotherapy-refractory\/ineligible cutaneous squamous cell carcinoma","volume":"15","author":"Marin-Acevedo","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2025.101967_bib39","doi-asserted-by":"crossref","first-page":"9520","DOI":"10.1200\/JCO.2022.40.16_suppl.9520","article-title":"Immunotherapy followed by cetuximab in locally advanced\/metastatic (LA\/M) cutaneous squamous cell carcinomas (cSCC): The I-TACKLE trial","volume":"40","author":"Bossi","year":"2022","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.101967_bib40","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1172\/JCI27745","article-title":"CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T\u00a0cells","volume":"116","author":"Quezada","year":"2006","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2025.101967_bib41","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2025.101967_bib42","article-title":"Profiling of immune features to predict immunotherapy efficacy","volume":"3","author":"Ye","year":"2022","journal-title":"Innovation"},{"key":"10.1016\/j.xcrm.2025.101967_bib43","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer","volume":"183","author":"Ott","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.101967_bib44","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.101967_bib45","first-page":"3325","article-title":"Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model","volume":"57","author":"Foster","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.101967_bib46","first-page":"21","article-title":"Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen","volume":"56","author":"Lin","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.101967_bib47","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djp079","article-title":"Dose escalation methods in phase I cancer clinical trials","volume":"101","author":"Le Tourneau","year":"2009","journal-title":"J.\u00a0Natl. Cancer Inst."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125000400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125000400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T20:36:38Z","timestamp":1772483798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125000400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2666379125000400"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.101967","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanrilkefusp alfa (SOT101), an IL-15 receptor \u03b2\u03b3 superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.101967","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101967"}}